Is Mono Pharmacare overvalued or undervalued?

As of 15 September 2025, the valuation grade for Mono Pharmacare has moved from expensive to fair. Based on the current analysis, the company appears to be fairly valued. The PE ratio stands at 13.32, the EV to EBITDA ratio is 10.78, and the PEG ratio is notably low at 0.50, indicating potential for growth relative to its price.
In comparison to its peers, Mono Pharmacare's valuation metrics are significantly more attractive. For instance, Sun Pharma has a PE ratio of 33.52 and an EV to EBITDA of 22.67, while Divi's Lab shows a PE of 69.55 and an EV to EBITDA of 50.96, both categorized as very expensive. Additionally, despite a challenging year-to-date return of -29.44%, Mono's recent performance has outpaced the Sensex over the past week with a return of 13.46% compared to the Sensex's 1.20%.